Lv1
50 积分 2023-11-07 加入
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
1天前
已完结
成人T细胞白血病/淋巴瘤临床病理学特征
1天前
已完结
恶性肿瘤临床试验中短期中间指标与终点指标相关性Meta分析的系统评价
5天前
已完结
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
13天前
已完结
多发性骨髓瘤中循环骨髓瘤细胞水平及临床意义
13天前
已关闭
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
19天前
已完结
异基因造血干细胞移植后植入功能不良的危险因素分析
22天前
已完结
移植后铁蛋白升高预测异基因造血干细胞移植血小板植入延迟
23天前
已完结
DRG背景下基于循证药学制订药物治疗临床路径实践探索
1个月前
已完结
皖公网安备34019202002308
